Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

NGM BIOPHARMACEUTICALS INC (NGM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 SC 13G/A BlackRock Inc. reports a 4.6% stake in NGM BIOPHARMACEUTICALS INC
08/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/07/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/04/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights"
06/08/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Open Market Sale AgreementSM, between the Company and Jefferies"
05/12/2023 4 Guyer Shelly D (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 78,407 options to buy @ $3.69, valued at $289.3k
05/12/2023 4 RIEFLIN WILLIAM JL (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 78,407 options to buy @ $3.69, valued at $289.3k
05/12/2023 4 Hooper Suzanne Sawochka (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 78,407 options to buy @ $3.69, valued at $289.3k
05/12/2023 4 GOEDDEL DAVID V (10% Owner) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 78,407 options to buy @ $3.69, valued at $289.3k
05/12/2023 4 PERLMUTTER ROGER M (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 78,407 options to buy @ $3.69, valued at $289.3k
05/12/2023 4 Ho Carole (Director) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 78,407 options to buy @ $3.69, valued at $289.3k
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/04/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "How The Decision Was Reached"
03/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 ARS Form ARS - Annual Report to Security Holders:
03/06/2023 4 Nolan Mangini Siobhan (President and CFO) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 76,000 shares @ $0
Granted 228,000 options to buy @ $4.36, valued at $994.1k
Granted 200,000 options to buy @ $4.36, valued at $872k
03/06/2023 4 WOODHOUSE DAVID J (CEO) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 127,200 shares @ $0
Granted 381,600 options to buy @ $4.36, valued at $1.7M
Granted 500,000 options to buy @ $4.36, valued at $2.2M
03/06/2023 4 Lieu Hsiao D (SVP, Chief Medical Officer) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 53,000 shares @ $0
Granted 159,000 options to buy @ $4.36, valued at $693.2k
03/06/2023 4 CHEN JIN-LONG (Chief Scientific Officer) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 64,000 shares @ $0
Granted 192,000 options to buy @ $4.36, valued at $837.1k
Granted 175,000 options to buy @ $4.36, valued at $763k
03/06/2023 4 Pierce Valerie L (SVP, GC & CCO) has filed a Form 4 on NGM BIOPHARMACEUTICALS INC
Txns: Granted 49,000 shares @ $0
Granted 147,000 options to buy @ $4.36, valued at $640.9k
Granted 150,000 options to buy @ $4.36, valued at $654k
03/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.5% stake in NGM Biopharmaceuticals Inc.
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy